Do you want to read an article? Please log in or register.
Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
BJU Int
McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA
doi: 10.1111/bju.70044
Genitourinary Cancer
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy
BJU Int
Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
doi: 10.1111/bju.16895
COMMENTED
Genitourinary Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group
doi: 10.1200/JCO-25-01324
Genitourinary Cancer
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
J Urol
Prasad SM, Shishkov D, Mihaylov NV, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Burger B, Meads A, Schoenberg M
doi: 10.1097/JU.0000000000005041
Genitourinary Cancer
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer
BJU Int
Abou Chakra M, McElree IM, Mott SL, O'Donnell MA
doi: 10.1111/bju.70149
COMMENTED
Genitourinary Cancer
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Bladder Cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Lerner SP, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora PM, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel RT, Templeton AJ, Vogl U, Wettstein MS, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser CD
doi: 10.1177/23523735251410823
Genitourinary Cancer
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer
BJU Int
Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, Katzendorn O, Krajewski W, Laukhtina E, Elena JLR, Aranda J, Contieri R, Hurle R, Subiela JD, Lucena PE, Fernández A, Marcq G, Szostek A, Pichler R, Álvarez-Maestro M, Bazán AA, Klatte T, du Biest AM, Ferrando V, Buisan O, López AV, Soria F, Pradere B, D Andrea D, Shariat SF, Colecchia M, Montorsi F, Briganti A, Gontero P, Xylinas E, Moschini M, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators
doi: 10.1111/bju.70182
Genitourinary Cancer
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Eur Urol
Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M, Necchi A, Oualla K, Pohar KS, Rosenberg JE, Schmidt B, Siefker-Radtke AO, Steinberg GD, Stenzl A, Buckley RJ, Kamat AM
doi: 10.1016/j.eururo.2026.01.029
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022